Health-care companies fell as traders rotated into faster-growing sectors.
Obesity drugmakers rose after one challenger stumbled. Structure Therapeutics' potential rival to Eli Lilly in weight-loss drugs missed early-stage testing expectations, causing shares of Structure to plummet. Eli Lilly and Novo Nordisk gained, as their lead in the booming weight-loss category looked set to last.
Gene-sequencing company Illumina said it will divest itself of cancer blood test maker Grail, following Illumina's loss in its legal battle against U.S. antitrust regulators.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
12-18-23 1813ET
